Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral Load

Completed · Phase 2

Conditions studied: HIV Infections

In brief

The purpose of this study is to determine if HIV-specific canarypox vaccine and/or interleukin-2 (IL-2) will control viral load (amount of HIV in the blood) after HIV treatment is withdrawn for a certain time period.

Key facts

Study ID
NCT00013663
Run by
National Institute of Allergy and Infectious Diseases (NIAID)
People needed
92
Expected to finish
2006-06-01
Last updated by the study team
2012-11-02

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.